Immunology vs Ophthalmology — Deal Terms Comparison

Immunology Median Upfront

$480M

Total: $2.5B

Ophthalmology Median Upfront

$768M

Total: $3.6B

Immunology Royalties

13.2%-22.1%

Tiered to 26.1%

Ophthalmology Royalties

10.2%-20.4%

Tiered to 24.4%

Model Your Deal

Market Analysis

Immunology and Ophthalmology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 immunology deals carry a median total deal value of $2.5B with $480M upfront, compared to $3.6B total value and $768M upfront for ophthalmology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Immunology deals allocate 19% to upfront and 81% to milestones, while Ophthalmology deals split 21%/79%. Development milestones are $405M for immunology versus $569M for ophthalmology, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do immunology and ophthalmology deal terms compare?

Immunology Phase 2 deals average $2.5B total value ($480M upfront), while Ophthalmology deals average $3.6B ($768M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Immunology or Ophthalmology?

Immunology base royalties range from 13.2% to 22.1%, while Ophthalmology royalties range from 10.2% to 20.4%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between immunology and ophthalmology?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Immunology and Ophthalmology each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough